Vaccines Pipeline
Vaccine Late-Stage Hits and Misses, 2024 to 2026
CMV Phase 3 miss, norovirus interim analysis short of early-success criteria, mFLUSIVA approval, Capvaxive launch, and intismeran still the oncology option.
Oct 2025
- Asset:
- mRNA-1647 CMV
- Company:
- Moderna
- Result:
- Phase 3 miss
- Note:
- 6% to 23% efficacy. Congenital program discontinued.
2026
- Asset:
- mRNA-1403 norovirus
- Company:
- Moderna
- Result:
- Phase 3 interim analysis
- Note:
- Did not meet statistical criteria for early success. Trial ongoing and blinded; additional cohort planned.
5 Aug 2026
- Asset:
- mFLUSIVA (mRNA-1010)
- Company:
- Moderna
- Result:
- FDA approved, adults 50+
- Note:
- First US mRNA flu shot. Study P304 relative vaccine efficacy 26.6% (95% CI 16.7 to 35.4) vs standard-dose for RT-PCR-confirmed influenza-like illness in adults 50+ (411 vs 557 cases). ACIP and contracting still pending for 2026-27 volume.
19 Aug 2026
- Asset:
- Intismeran autogene + Keytruda (INTerpath-001)
- Company:
- Moderna / Merck
- Result:
- Phase 3 melanoma hit (RFS, DMFS)
- Note:
- Met RFS (primary) and DMFS (key secondary) vs Keytruda alone in 1,137 resected stage IIB-IV patients (2:1). Detail released 22 Oct 2026 ahead of ESMO LBA1: RFS HR 0.58 (95% CI 0.45 to 0.75; 42% lower risk of recurrence or death) and DMFS HR 0.62 (95% CI 0.45 to 0.85), median follow-up 24.6 months. OS not yet mature; companies say they are engaging regulators. Phase 2b five-year: 49% cut in recurrence or death vs Keytruda alone.
2024-2025
- Asset:
- Capvaxive
- Company:
- Merck
- Result:
- Launch hit
- Note:
- $759M in first full year. Adult pneumococcal share taker versus Prevnar.
Jun 2025
- Asset:
- Enflonsia (clesrovimab)
- Company:
- Merck
- Result:
- FDA approved
- Note:
- Infant RSV mAb. Sales not yet a disclosed franchise line.
Named Shots After Congenital CMV
Lyme VALOR (statistical miss, Pfizer still filing), Qdenga commercial, CMV transplant Phase 2 still on, HEPLISAV-B nine-month sales. Not respiratory, not intismeran.
LB6V (formerly VLA15) Lyme
- Company:
- Pfizer / Valneva
- Status:
- Phase 3 VALOR. EMA validated the EU marketing authorization application on 14 Aug 2026 and began its assessment; Pfizer planned submissions (23 Mar 2026 PR)
- Printed mark:
- 73.2% reduction in confirmed Lyme vs placebo from 28 days post-dose 4 (95% CI 15.8, 93.5). The pre-set criterion (CI lower bound above 20) was not met in the first pre-specified analysis because fewer cases accrued than planned. Second analysis lower bound was above 20.
Qdenga dengue
- Company:
- Takeda
- Status:
- Commercial. WHO prequalified. Available in more than 30 countries per the FY2025 presentation
- Printed mark:
- JPY 40.8B sales in FY2025 (year ended 31 Mar 2026), +10.7% CER. Plan to manufacture 21 million doses in FY2026.
mRNA-1647 congenital CMV
- Company:
- Moderna
- Status:
- Discontinued October 2025
- Printed mark:
- Phase 3 (NCT05085366) did not meet the primary endpoint. Vaccine efficacy 6% to 23% depending on case definition. Not a remaining commercial bet.
mRNA-1647 CMV in HCT
- Company:
- Moderna
- Status:
- Phase 2 ongoing
- Printed mark:
- NCT05683457. ClinicalTrials.gov: active, not recruiting. Actual enrollment 84. No efficacy print. Do not treat congenital discontinuation as a transplant readout.
HEPLISAV-B adult HepB
- Company:
- Dynavax / Sanofi
- Status:
- Commercial. Sanofi completed its Dynavax acquisition on 10 Feb 2026 (agreement dated 23 Dec 2025, announced 24 Dec 2025)
- Printed mark:
- 9M 2025 net product revenue $246.8M (Dynavax Q3 2025). FY 2025 is not taken from a 10-K here. Not a peak-sales model.
Z-1018 shingles
- Company:
- Sanofi / Dynavax
- Status:
- Pipeline challenger inside the Dynavax deal
- Printed mark:
- No 2026 US commercial competitor to Shingrix. Long-dated. No Phase 3 efficacy number printed for a 2026 launch.
Personalized Cancer Vaccine Trials
Intismeran autogene with Merck versus BioNTech iNeST. Option-value, not 2026 product revenue.
Intismeran autogene (mRNA-4157 / V940) + Keytruda
- Company:
- Moderna / Merck
- Setting:
- Adjuvant melanoma; other tumors in INTerpath
- Evidence:
- Phase 3 INTerpath-001 (topline 19 Aug 2026, detail 22 Oct 2026): at the primary pre-specified analysis (intention-to-treat, median follow-up 24.6 months) the combination cut the risk of recurrence or death by 42% (RFS, HR 0.58, 95% CI 0.45 to 0.75, p<0.001) and of distant metastasis or death by 38% (DMFS, HR 0.62, 95% CI 0.45 to 0.85, p=0.002) vs Keytruda alone; OS not yet mature. Phase 2b five-year: 49% reduction in recurrence or death vs Keytruda alone
- 2026 commercial:
- No 2026 product revenue. Phase 3 melanoma is the filing gate; the companies say they are engaging with regulatory authorities, with no filing date given.
iNeST individualized neoantigen
- Company:
- BioNTech / Genentech
- Setting:
- Solid tumors
- Evidence:
- Colorectal Phase 2 (BNT122-01, vs watchful waiting) terminated 28 Aug 2026 after a DSMB-noted numerical imbalance in overall survival. Pancreatic Phase 2 (IMcode003) continues
- 2026 commercial:
- BioNTech guided no oncology product revenue in 2026. Vaccines are the cash residual.
Pumitamig (PD-L1/VEGF-A) + BMS
- Company:
- BioNTech / BMS
- Setting:
- Not a vaccine
- Evidence:
- €613M collaboration revenue recognized in Q3 2025
- 2026 commercial:
- Shown so readers do not confuse BMS collab cash with Comirnaty.
Vaccine CBER and EMA Decision Calendar
Dates that can move MRNA, GSK, SNY, PFE, and BNTX. ACIP still sits after FDA for coverage.
5 Aug 2026
- Asset:
- mFLUSIVA
- Agency:
- FDA
- Status:
- Approved, adults 50+ (65+ under accelerated approval, continued approval may depend on a confirmatory trial)
- Why it moves the stock:
- Unlocks mRNA flu and the combo path. Volume still needs ACIP.
19 Aug 2026
- Asset:
- Intismeran Phase 3 melanoma
- Agency:
- FDA path TBD
- Status:
- Phase 3 met RFS and DMFS (RFS HR 0.58, 95% CI 0.45 to 0.75); companies say they are engaging regulators, no filing date given
- Why it moves the stock:
- Largest remaining mRNA option after the CMV Phase 3 miss and norovirus missing early-success criteria at its interim analysis. Detailed results released 22 Oct 2026 ahead of ESMO (23-27 Oct).
27 Aug 2026
- Asset:
- Comirnaty, Spikevax, mNEXSPIKE (2026-27 XFG formula)
- Agency:
- FDA
- Status:
- Approved. 65+ and high-risk younger people: Comirnaty from age 5, mNEXSPIKE from 12, Spikevax from 6 months. Nuvaxovid XFG: FDA page lists a 27 Aug 2026 approval letter (65+ and 12 to 64 high-risk), Novavax release 28 Aug
- Why it moves the stock:
- Seasonal COVID revenue for PFE, BNTX, MRNA and NVAX. FDA product pages list approval letters dated 27 Aug 2026.
23 Sep 2026
- Asset:
- 2026-27 COVID-19 vaccines
- Agency:
- CDC
- Status:
- Recommended for all adults 18+; children 6 months to 17 years: recommended if moderately or severely immunocompromised, otherwise shared decision-making
- Why it moves the stock:
- CDC clinical considerations page updated 23 Sep 2026. Use in ages under 65 without a high-risk condition is off-label.
2026-27 season
- Asset:
- mFLUSIVA ACIP
- Agency:
- CDC ACIP
- Status:
- No vote: CDC lists all three 2026 ACIP meetings (18-19 Mar, 24-26 Jun, 21-23 Oct) as cancelled due to ongoing litigation
- Why it moves the stock:
- Coverage and VFC/Medicare follow the vote, not the FDA letter.
9 Jul 2026
- Asset:
- mRESVIA EC joint procurement
- Agency:
- EC
- Status:
- Framework contract signed, announced by the EC 9 Jul 2026: up to 24M doses, six countries, no minimum purchase, up to four years
- Why it moves the stock:
- Public-sector RSV volume in six countries, but with no minimum purchase.
10 Feb 2026
- Asset:
- Sanofi-Dynavax close
- Agency:
- Deal / HSR
- Status:
- Completed 10 Feb 2026: tender offer at $15.50 a share (~$2.2B equity value, announced 24 Dec 2025) closed with 73.92% of shares tendered
- Why it moves the stock:
- HEPLISAV-B plus a shingles candidate (Z-1018, Phase 1/2). Dynavax 8-K of 10 Feb 2026 confirms the tender completed.
Vaccine M&A and Licensing, 2023 to 2026
CureVac, Dynavax, Matrix-M, Icosavax, and the Bavarian-Serum Institute chikungunya transfer.
AstraZeneca agrees to acquire Icosavax: $15.00 a share in cash plus a CVR of up to $5.00, about $838M upfront and up to $1.1B in equity value
Adds IVX-A12, a virus-like-particle vaccine candidate against RSV and hMPV in older adults. Merger agreement dated 11 Dec 2023; acquisition completed 19 Feb 2024.
BioNTech closes its CureVac exchange offer, about 86.75% of shares tendered
Per BioNTech, complements its mRNA design, delivery formulation and manufacturing capabilities. Compulsory acquisition of the remaining shares completed at the beginning of January 2026.
Sanofi agrees to buy Dynavax at $15.50 a share, about $2.2B
Adds HEPLISAV-B, a marketed adult hepatitis B vaccine, and the Phase 1/2 shingles candidate Z-1018. Agreement dated 23 Dec 2025; tender offer and merger completed 10 Feb 2026.
Novavax grants Pfizer a non-exclusive worldwide Matrix-M adjuvant license for one infectious disease, with a second at Pfizer's option
$30M upfront and up to $500M in milestones across both fields, plus tiered high mid-single-digit percentage royalties. Agreement dated 15 Jan 2026.
Bavarian Nordic and Serum Institute of India sign a chikungunya vaccine contract manufacturing agreement
Full tech transfer of the chikungunya vaccine (CHIKV VLP) for future supply to endemic low- and middle-income countries; it replaces the agreement previously entered with Biological E.
Disclosed Pipeline by Pathogen
Issuer programs only, not a Citeline census. After CMV, the map is respiratory plus one oncology option.
COVID
- What is left:
- Seasonal updates plus combos
- Lead names:
- Pfizer/BioNTech, Moderna, Sanofi/Novavax
- Status:
- Commercial. APA world is over.
Flu
- What is left:
- mRNA vs egg/cell/recombinant
- Lead names:
- Sanofi, Seqirus, GSK, Moderna mFLUSIVA
- Status:
- mFLUSIVA approved Aug 2026; ACIP pending. GSK mRNA flu (HA plus NA): positive Phase 2, Phase 3 efficacy trial planned to start Sep 2026.
RSV adult
- What is left:
- Share fight, not a new TAM
- Lead names:
- Arexvy, Abrysvo, mRESVIA
- Status:
- Single-dose ACIP. Combos are the next attempt to grow visits.
RSV infant
- What is left:
- mAb vs maternal vaccine
- Lead names:
- Beyfortus, Enflonsia, maternal Abrysvo
- Status:
- Beyfortus is the disclosed P&L.
CMV
- What is left:
- Mostly dead as a congenital mRNA bet
- Lead names:
- Moderna discontinued
- Status:
- Phase 3 miss Oct 2025.
Norovirus
- What is left:
- Retry
- Lead names:
- Moderna mRNA-1403
- Status:
- Phase 3 interim analysis did not meet early-success criteria (31 Jul 2026); trial continues.
HPV
- What is left:
- No near-term branded US challenger
- Lead names:
- Gardasil 9; SII Cervavac in LMIC
- Status:
- Country risk, not pipeline risk.
Shingles
- What is left:
- Long-dated challenger
- Lead names:
- Shingrix; Sanofi-Dynavax Z-1018
- Status:
- No 2026 US competitor.
Pneumococcal
- What is left:
- Valency race
- Lead names:
- Prevnar 20, Capvaxive, Vaxneuvance
- Status:
- Adult share fight is commercial, not Phase 3.
Oncology
- What is left:
- Personalized mRNA + checkpoint
- Lead names:
- Intismeran; BioNTech iNeST
- Status:
- Intismeran Phase 3 melanoma met RFS and DMFS (19 Aug 2026). iNeST colorectal Phase 2 terminated (28 Aug 2026). Option-value. No 2026 product revenue guided.
Adjuvant and Platform Bets
AS01, Matrix-M, CpG 1018, LNP IP, sa-mRNA, and protein/VLP. Who captures the next respiratory or endemic dollar.
AS01 adjuvant
- Owner:
- GSK
- Where it shows up:
- Shingrix, Arexvy
- Equity angle:
- Moat on the two biggest GSK vaccines. Not licensed out cheaply.
Matrix-M
- Owner:
- Novavax; licensed to Pfizer Jan 2026
- Where it shows up:
- Nuvaxovid; future Pfizer programs
- Equity angle:
- Turns NVAX into an adjuvant royalty plus a shrinking COVID P&L.
CpG 1018
- Owner:
- Dynavax / Sanofi (closed 10 Feb 2026)
- Where it shows up:
- HEPLISAV-B; shingles candidate Z-1018
- Equity angle:
- The Dynavax deal is an adjuvant and hepatitis B franchise, and a Shingrix shot across the bow.
LNP / Acuitas IP
- Owner:
- Acuitas (private) plus sponsors
- Where it shows up:
- Comirnaty, Spikevax, mRESVIA, mFLUSIVA
- Equity angle:
- IP and lipid supply, not a public pure-play in this roster.
sa-mRNA
- Owner:
- Arcturus; CSL Seqirus interest
- Where it shows up:
- Kostaive COVID in Japan
- Equity angle:
- Self-amplifying. Small-cap (ARCT), not a US seasonal franchise in 2026.
Protein / VLP
- Owner:
- Pfizer, GSK, Merck, Novavax, Sanofi
- Where it shows up:
- Abrysvo, Arexvy, Gardasil, Nuvaxovid
- Equity angle:
- Still most of the branded dollars.